Ran Zheng

Ran Zheng has a diverse range of work experience in the bioengineering and biotechnology fields. Most recently, they served as the Chief Executive Officer of Landmark Bio starting in March 2021. They are also currently a Board Member at Caribou Biosciences since September 2021. Prior to that, they worked at Orchard Therapeutics as the Chief Technical Officer from March 2019 to February 2021. Ran Zheng has a significant tenure at Amgen, where they held several leadership positions. From 2016 to 2019, they served as the Vice President of Development Supply Chain and Site Operations. They also held the role of Executive Director and Plant Manager from 2011 to 2015 and again from 2006 to 2010. Additionally, they held roles such as Associate Director in Quality Control and Process Development at Amgen from 2003 to 2006. Before joining Amgen, they worked as an Associate Director in Process Engineering at FUJIFILM Diosynth Biotechnologies from 2000 to 2003. They started their career at Sanofi Genzyme as a Process Development Engineer in BioEngineering from 1996 to 2000.

Ran Zheng has studied Microbial Engineering/Chemical Engineering at the University of Minnesota. Additionally, they have pursued a Women's Leadership Institute program at UCLA Anderson School of Management.